What Shionogi’s planned acquisition of IntraBio means for the NPC community
October 7, 2026
On 5 October 2026, Shionogi & Co., Ltd. announced that it had entered into an agreement to acquire IntraBio Inc., the company that developed AQNEURSA® (levacetylleucine).
Shionogi is a global pharmaceutical company headquartered in Osaka, Japan. The company has identified rare disease as a growing area of focus and says the planned acquisition will combine IntraBio’s rare disease expertise with Shionogi’s global resources and reach.
For the Niemann–Pick disease type C (NPC) community, the announcement is significant because AQNEURSA is approved to treat the neurological manifestations of NPC in the United States and European Union. Through the transaction, Shionogi would gain the global rights to AQNEURSA, including its intellectual property and commercialisation rights.
What happens next?
This is a proposed acquisition and the transaction has not yet been completed. It is subject to customary closing conditions and regulatory clearances, with completion currently planned between November and December 2026.
Until the transaction closes, IntraBio will continue to operate as an independent company. IntraBio has advised that there will be no interruption to patients’ access to AQNEURSA and that existing patient support services and access programs will continue during the transition.
What does this mean for Australia?
At this stage, the announcement does not provide any new information about an Australian regulatory submission, Therapeutic Goods Administration (TGA) approval or broader access to AQNEURSA in Australia.
ANPDF has requested an update through the International Niemann-Pick Disease Alliance (INPDA) on plans for Australia, including whether and when a submission to the TGA may be made. We are still awaiting further information and will share it with the Australian NPC community when it becomes available.
The acquisition may provide greater global resources and reach over time, but it is too early to know what practical effect it may have on the Australian pathway. The acquisition agreement should not be understood as Australian approval or confirmation that the treatment will become available here.
Our role during the transition
ANPDF will continue to advocate for timely and equitable access to evidence-based treatments for Australians living with NPC. Our information and updates from IntraBio are provided through the International Niemann-Pick Disease Alliance (INPDA).
INPDA will continue to work with IntraBio during the transition and establish relationships with Shionogi as the process moves forward. As Australia’s representative to INPDA, ANPDF will continue to ensure the needs and perspectives of Australian families are included in these discussions.
We understand that announcements about treatments and company changes can bring both hope and questions. We will provide further updates as soon as there is confirmed information relevant to Australia.
This update is for general information only and is not medical advice. Families with questions about treatment should speak with their treating clinician.
Read Shionogi’s full announcement: Shionogi Continues Rare Disease Expansion With Planned Acquisition of IntraBio Inc.
or the Press Release for Community here:
To join our fight, as well as fund vital research for a cure, support the Australian NPC Disease Foundation in its goals of "Research. Cure. Persevere."
Ways to support NP-C in Australia:
Shop at our online NPC store
Fundraise your way! Check our free resources and inspo online.
References:
Shionogi & Co., Ltd. (2026, October 5). Shionogi Continues Rare Disease Expansion With Planned Acquisition of IntraBio Inc. https://www.shionogi.com/global/en/news/2026/10/20261005_02.html shionogi.com
IntraBio Inc. (2024, September 25). IntraBio Announces U.S. FDA Approval of AQNEURSA for the Treatment of Niemann-Pick Disease Type C. https://intrabio.com/news/intrabio-announces-u-s-fda-approval-of-aqneursa-for-the-treatment-of-niemann-pick-disease-type-c/ IntraBio
IntraBio Inc. (2026, January 21). IntraBio Receives European Commission Approval of AQNEURSA® for the Treatment of Niemann-Pick Type C Disease. https://intrabio.com/news/intrabio-receives-european-commission-approval-of-aqneursa-for-the-treatment-of-niemann-pick-type-c-disease/
Comments